Insulet (PODD) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue grew 30% year-over-year to $569 million, driven by strong Omnipod 5 adoption in both U.S. and international markets, with Omnipod 5 launches in up to 14 countries and clinical data showing a 0.8% HbA1c reduction.

• Gross margin reached 71.9%, the highest in the diabetes technology sector, with adjusted operating margin at 16.4%.

• Net income was $35.4 million, down from $51.5 million in the prior year quarter, primarily due to a $39.5 million loss on extinguishment of debt.

• New CEO Ashley McEvoy affirmed the current growth strategy, emphasizing innovation, global expansion, and a focus on both Type 1 and Type 2 diabetes markets.

• Over 85% of U.S. new customer starts came from MDI, and over 30% were Type 2, reflecting successful expansion into new patient segments.

Financial highlights

• Q1 2025 total revenue: $569 million, up 30% year-over-year; U.S. Omnipod revenue up 26.4% to $401.7 million, international Omnipod up 32.2% to $152.4 million.

• Gross margin: 71.9%, up 240 basis points year-over-year; adjusted operating margin: 16.4%; adjusted EBITDA: $133.9 million (23.5% margin).

• Drug Delivery revenue was $14.9 million, up 71.3% year-over-year.

• Cash and cash equivalents totaled $1.3 billion at quarter-end; no outstanding borrowings under the $500 million revolving credit facility.

• Diluted share count expected to decrease by 5% year-over-year.

Outlook and guidance

• FY 2025 revenue growth guidance raised to 19%-22% for total company, 20%-23% for Omnipod; Q2 2025 revenue growth expected at 23%-26% (constant currency).

• U.S. Omnipod revenue projected to grow 18%-21%, international Omnipod 27%-30% in 2025.

• Gross margin guidance raised to approximately 71% for 2025, absorbing a 50 basis point tariff impact; adjusted operating margin guidance reaffirmed at 16.5%.

• R&D and SG&A expenses expected to increase as investments continue in innovation, international expansion, and support infrastructure.

• Capital expenditures projected to rise in 2025 to support manufacturing and global expansion.